Original Publication Date: 1 April, 2016
Publication / Source: Immunotherapy
Authors: Sherise D Ferguson, Visish M Srinivasan, Michael GZ Ghali & Amy B Heimberger
Malignant gliomas, including glioblastoma (GBM), are the most common primary brain tumors. Despite extensive research only modest gains have been made in long-term survival. Standard of care involves maximizing safe surgical resection followed by concurrent chemoradiation with temozolomide. Immunotherapy for GBM is an area of intense research in recent years. New immunotherapies, although promising, have not been integrated into standard practice. Human cytomegalovirus (HCMV) is a DNA virus of the family Herpesviridae.